$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000114420413008537 Filed on February 14, 2013

Income Statement

Concept	2013 Q1	2012 Q4	2011 Q4
Revenue	$1.251M	$975.5K	$1.229M
YoY Change	-5.0%	-20.61%	-0.91%
Cost Of Revenue	$1.066M	$1.134M	$1.030M
YoY Change	-4.27%	10.13%	-8.06%
Gross Profit	$185.9K	-$158.6K	$198.9K
YoY Change	-8.97%	-179.75%	53.0%
Gross Profit Margin	14.85%	-16.26%	16.19%
Selling, General & Admin	$854.9K	$791.7K	$801.3K
YoY Change	2.4%	-1.2%	2.73%
% of Gross Profit	459.85%		402.86%
Research & Development	$155.1K	$149.2K	$189.7K
YoY Change	17.32%	-21.35%	-245.89%
% of Gross Profit	83.45%		95.36%
Depreciation & Amortization	$180.0K	$180.0K	$230.0K
YoY Change	-14.29%	-21.74%	-8.0%
% of Gross Profit	96.82%		115.64%
Operating Expenses	$1.010M	$940.8K	$990.9K
YoY Change	4.44%	-5.06%	30.39%
Operating Profit	-$824.1K	-$1.099M	-$792.1K
YoY Change	8.03%	38.81%	25.72%
Interest Expense	$110.0K	-$50.00K	$160.0K
YoY Change	-47.62%	-131.25%	-60.98%
% of Operating Profit
Other Income/Expense, Net	$109.1K	-$54.87K	$163.3K
YoY Change	-48.05%	-133.6%
Pretax Income	-$720.0K	-$1.150M	-$630.0K
YoY Change	30.91%	82.54%	173.91%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$715.0K	-$1.154M	-$628.7K
YoY Change	29.33%	83.59%	173.37%
Net Earnings / Revenue	-57.14%	-118.34%	-51.17%
Basic Earnings Per Share
Diluted Earnings Per Share	-$20.80K	-$33.24K	-$23.00K
COMMON SHARES
Basic Shares Outstanding	34.61M	34.60M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q4	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.680M	$4.440M	$3.380M
YoY Change	46.03%	31.36%	22.02%
Cash & Equivalents	$3.684M	$4.441M	$3.436M
Short-Term Investments
Other Short-Term Assets	$210.0K	$230.0K	$120.0K
YoY Change	23.53%	91.67%	-52.0%
Inventory	$357.0K	$402.9K	$810.0K
Prepaid Expenses
Receivables	$830.0K	$656.2K	$830.0K
Other Receivables	$10.00K	$0.00	$20.00K
Total Short-Term Assets	$5.092M	$5.736M	$5.160M
YoY Change	27.1%	11.17%	7.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.853M	$2.029M	$2.790M
YoY Change	-28.5%	-27.29%	-21.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$293.6K	$301.1K	$230.0K
YoY Change	-2.03%	30.9%	-32.35%
Total Long-Term Assets	$2.797M	$2.981M	$3.290M
YoY Change	-21.94%	-9.4%	-20.91%
TOTAL ASSETS
Total Short-Term Assets	$5.092M	$5.736M	$5.160M
Total Long-Term Assets	$2.797M	$2.981M	$3.290M
Total Assets	$7.890M	$8.717M	$8.450M
YoY Change	3.95%	3.16%	-5.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$370.0K	$390.0K	$350.0K
YoY Change	5.71%	11.43%	-22.22%
Accrued Expenses	$280.0K	$300.0K	$410.0K
YoY Change	0.0%	-26.83%	13.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$649.3K	$696.8K	$760.0K
YoY Change	3.7%	-8.31%	-12.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$910.0K	$1.000M	$1.010M
YoY Change	12.35%	-0.99%	-47.94%
Total Long-Term Liabilities	$910.0K	$1.000M	$1.010M
YoY Change	12.35%	-0.99%	-50.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$649.3K	$696.8K	$760.0K
Total Long-Term Liabilities	$910.0K	$1.000M	$1.010M
Total Liabilities	$1.555M	$1.694M	$1.770M
YoY Change	8.04%	-4.28%	-39.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.10M	-$50.38M
YoY Change	8.65%
Common Stock	$34.61K	$34.61K
YoY Change	18.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.390K	$8.390K
YoY Change	0.0%
Treasury Stock Shares	13.20K shares	$13.20K
Shareholders Equity	$6.335M	$7.022M	$6.680M
YoY Change
Total Liabilities & Shareholders Equity	$7.890M	$8.717M	$8.450M
YoY Change	3.95%	3.16%	-5.69%

Cashflow Statement

Concept	2013 Q1	2012 Q4	2011 Q4
OPERATING ACTIVITIES
Net Income	-$715.0K	-$1.154M	-$628.7K
YoY Change	29.33%	83.59%	173.37%
Depreciation, Depletion And Amortization	$180.0K	$180.0K	$230.0K
YoY Change	-14.29%	-21.74%	-8.0%
Cash From Operating Activities	-$760.0K	-$570.0K	-$470.0K
YoY Change	-6.17%	21.28%	-27.69%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%	-66.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$261.1K
YoY Change			-89.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-10.00K	2.270M
YoY Change		-100.44%	-6.2%
NET CHANGE
Cash From Operating Activities	-760.0K	-570.0K	-470.0K
Cash From Investing Activities	0.000	0.000	-10.00K
Cash From Financing Activities	0.000	-10.00K	2.270M
Net Change In Cash	-760.0K	-580.0K	1.790M
YoY Change	-10.59%	-132.4%	2.87%
FREE CASH FLOW
Cash From Operating Activities	-$760.0K	-$570.0K	-$470.0K
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$760.0K	-$570.0K	-$460.0K
YoY Change	-1.3%	23.91%	-25.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34611517
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ISORAY, INC.
	isr	Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights	0.6472
CY2012Q3	isr	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	3500000	USD
	isr	Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares	2766
CY2012Q3	isr	Payments Of Stock Issuance Costs Commission Expense PaymentsOfStockIssuanceCostsCommissionExpense	87500	USD
CY2012Q3	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	67306	USD
CY2012Q3	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	47000	USD
CY2012Q3	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	6217	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	13477	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	4020	USD
	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableExercisedInPeriod	29478
	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableForfeitedInPeriod	36422
	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedInPeriod	27278
	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedInPeriod	35480
	isr	Supplemental Common Stock Warrant Liability SupplementalCommonStockWarrantLiability		USD
	isr	Supplemental Common Stock Warrant Liability SupplementalCommonStockWarrantLiability	484000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	393225	USD
CY2012Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	389105	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	656168	USD
CY2012Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	865056	USD
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	84776	USD
CY2012Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	88006	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57378917	USD
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54030311	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	14024	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	16390	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57789	USD
CY2012Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28826	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66379	USD
CY2011Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33190	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	44127	USD
CY2012Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	57604	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4328170
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6860357
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	33211	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	30362	USD
CY2012Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	757509	USD
CY2012Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	724298	USD
CY2012Q4	us-gaap	Assets Assets	8716787	USD
CY2012Q2	us-gaap	Assets Assets	7505482	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	5736162	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	4136153	USD
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4440703	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2672711	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2112254	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3436123	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1767992	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1268869	USD
CY2012Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.38
CY2012Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.38
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1957033
CY2012Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1959799
CY2011Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	713601
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193000000
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193000000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34611517
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30950108
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34611517
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30950108
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	34612	USD
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	30950	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2210740	USD
CY2012Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1134083	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2176832	USD
CY2011Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1029757	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	61511	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	388171	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	435464	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	240000	USD
CY2012Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	314000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"><strong>2.</strong></td> <td style="TEXT-ALIGN: justify"><strong>New Accounting Pronouncements</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") or other standards setting bodies that are adopted by us as of the specified effective dates. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position, results of operations and cash flows upon adoption.</p> <!--EndFragment--></div> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2012Q2	us-gaap	Liabilities Liabilities	1687290	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	129062	USD
CY2012Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	119881	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P9M15D
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	109561	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1114412	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	469559	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1150095	USD
CY2011Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	497168	USD
	us-gaap	Gross Profit GrossProfit	-179051	USD
CY2012Q4	us-gaap	Gross Profit GrossProfit	-158626	USD
	us-gaap	Gross Profit GrossProfit	265240	USD
CY2011Q4	us-gaap	Gross Profit GrossProfit	198898	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4120	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-17377	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-222365	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32009	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	9181	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	84252	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34682	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	84	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	161	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	6	USD
CY2012Q4	us-gaap	Interest And Debt Expense InterestAndDebtExpense		USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	3056	USD
CY2011Q4	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2962	USD
	us-gaap	Interest Paid InterestPaid	6	USD
	us-gaap	Interest Paid InterestPaid	77	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4808	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-41433	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56335	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	13750	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-25243	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	24000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	24000	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-3230	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	10101	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1914	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-405287	USD
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	55663	USD
CY2012Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	68386	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	402912	USD
CY2012Q2	us-gaap	Inventory Net InventoryNet	444345	USD
CY2012Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2012Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	130889	USD
CY2012Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	261835	USD
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	216360	USD
CY2012Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	114124	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	272	USD
CY2012Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	128	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	455	USD
CY2011Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	268	USD
CY2012Q4	us-gaap	Liabilities Liabilities	1694322	USD
CY2011Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-631403	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	74266	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8716787	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7505482	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	696813	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	648992	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3294479	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2310665	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13491	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27700	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1512996	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1014096	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2147995	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-1154327	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1730969	USD
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-628745	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2153311	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1156985	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1736285	USD
CY2012Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-54872	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	163399	USD
CY2011Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	163306	USD
	us-gaap	Operating Expenses OperatingExpenses	2043210	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	940829	USD
	us-gaap	Operating Expenses OperatingExpenses	2159608	USD
CY2011Q4	us-gaap	Operating Expenses OperatingExpenses	990949	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2222261	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1099455	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1894368	USD
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-792051	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13750	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	301074	USD
CY2012Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	301691	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3291977	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2279701	USD
CY2012Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3291977	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11309	USD
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	144116	USD
CY2012Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	52000	USD
CY2012Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	8011	USD
CY2012Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	9925	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13407	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9491	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18048	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5316	USD
CY2012Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5316	USD
CY2011Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	228368	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1352	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1825	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	40244	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2028682	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2416853	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	8960	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	5200	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned		USD
CY2012Q4	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned		USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	50000	USD
CY2011Q4	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned		USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	290648	USD
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149176	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	440975	USD
CY2011Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	189661	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181111	USD
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181027	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50382733	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48234738	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2031689	USD
CY2012Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	975457	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2442072	USD
CY2011Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1228655	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	57789	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	66379	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2037064
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.93
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13866	USD
CY2012Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	322094	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	618538	USD
CY2011Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	304120	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2964	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	37534
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	283372	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2312072
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	638150	USD
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2381306
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M13D
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	280472	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2037064
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2102964
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y10M2D
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	258411	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2221210
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2283968
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.87
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y26D
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34604605
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	240000	USD
CY2011Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	484000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27540492
CY2011Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28593845
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34238401
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	7022465	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	5818192	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31700
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5200
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	13200
CY2012Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2012Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	74000	USD
CY2012Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-55000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	166000	USD
CY2011Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	166000	USD

Files In Submission

Name	View Source	Status
0001144204-13-008537-index-headers.html	Edgar Link	pending
0001144204-13-008537-index.html	Edgar Link	pending
0001144204-13-008537.txt	Edgar Link	pending
0001144204-13-008537-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
isr-20121231.xml	Edgar Link	completed
isr-20121231.xsd	Edgar Link	pending
isr-20121231_cal.xml	Edgar Link	unprocessable
isr-20121231_def.xml	Edgar Link	unprocessable
isr-20121231_lab.xml	Edgar Link	unprocessable
isr-20121231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v332986_10q.htm	Edgar Link	pending
v332986_ex31-1.htm	Edgar Link	pending
v332986_ex31-2.htm	Edgar Link	pending
v332986_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2013 Q1 Form 10-Q Financial Statement

#000114420413008537 Filed on February 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2013 Q1 Form 10-Q Financial Statement

#000114420413008537 Filed on February 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx